HURA revenueQ1 2026$0
HURA revenue was $0 in fiscal Q1 2026 (ended Mar 31, 2026), compared with $0 a year earlier. For the full fiscal 2025 it was $0, compared with $0 in fiscal 2024.
TuHURA Biosciences Inc. (HURA) financials
For the twelve months ended Mar 31, 2026, TuHURA Biosciences Inc. reported $0 of revenue and -$30.92M of net income.
- Revenue, TTM
- $0
- Net income, TTM
- -$30.92M
- Free cash flow, TTM
- -$27.39M
- EPS, diluted, TTM
- -$0.61
- Cash
- $996.0K
- Total debt
- $3.60M
- Market cap
- $105.8M
FY2024FY2025
FY2015FY2025
FY2022FY2025
HURA revenue and earnings growth
HURA net incomeQ2 2026-$9.22M
HURA net income was -$9.22M in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$9.52M a year earlier. For the full fiscal 2025 it was -$30.05M, compared with -$21.68M in fiscal 2024.
HURA EPSQ2 2026-$0.14
HURA diluted EPS was -$0.14 in fiscal Q2 2026 (ended Jun 30, 2026). For the full fiscal 2025 it was -$0.63.
HURA free cash flowQ2 2026-$8.77M
HURA free cash flow was -$8.77M in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$6.25M a year earlier. For the full fiscal 2025 it was -$27.71M, compared with -$14.79M in fiscal 2024.
Income statement
| Line item | Dec 31, 2025 | Dec 31, 2024 | Jun 30, 2022 | Jun 30, 2021 | Jun 30, 2020 | Jun 30, 2019 | Jun 30, 2018 | Jun 30, 2017 | Jun 30, 2016 | Jun 30, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | - | - | - | - | - | - | - | - |
| Research and development | $20.53M | $13.34M | $15.17M | $11.81M | $3.63M | $3.66M | -$7.13M | -$5.00M | $3.36M | $2.56M |
| Selling, general and admin | $7.58M | $3.87M | $7.51M | $9.76M | $4.51M | $4.74M | -$4.04M | -$3.32M | $2.85M | $2.17M |
| Interest expense | $625.3K | $4.14M | - | $30.0K | - | - | - | - | - | $2.1K |
| Pre-tax income | -$30.05M | -$21.68M | - | - | - | - | - | - | - | - |
| Income tax | $1.6K | $3.8K | - | - | - | - | - | - | - | - |
| Net income | -$30.05M | -$21.68M | -$22.66M | -$38.30M | -$9.13M | -$8.05M | $11.14M | $8.08M | $8.86M | -$4.35M |
| EPS, basic | -$0.63 | -$1.21 | -$25.80 | -$1.60 | -$0.87 | $3.16 | $5.42 | $0.74 | $0.83 | $0.46 |
| EPS, diluted | -$0.63 | -$1.21 | - | - | - | - | - | - | - | $0.11 |
| Diluted shares | 47.9M | 18.7M | - | - | - | - | - | - | - | 38.1M |
Balance sheet
| Line item | Dec 31, 2025 | Dec 31, 2024 | Jun 30, 2022 | Jun 30, 2021 | Jun 30, 2020 | Jun 30, 2019 | Jun 30, 2018 | Jun 30, 2017 | Jun 30, 2016 | Jun 30, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $3.62M | $12.66M | $11.78M | $10.54M | $2.39M | $3.72M | $5.97M | $6.59M | $6.16M | $1.75M |
| Current assets | $4.62M | $19.61M | $13.26M | $11.79M | $2.85M | $4.03M | $7.05M | $7.87M | $6.32M | $2.58M |
| Goodwill | $10.74M | - | - | - | - | - | - | - | - | - |
| Total assets | $27.35M | $19.97M | $15.95M | $13.54M | $2.94M | $4.04M | $7.07M | $7.91M | $6.36M | $2.58M |
| Current liabilities | $5.92M | $5.33M | $3.99M | $2.78M | $2.67M | $2.07M | $1.64M | $1.30M | $627.4K | $853.1K |
| Short-term debt | - | - | - | - | - | - | - | $33.1K | - | - |
| Long-term debt | - | - | - | - | - | - | - | - | $693.7K | $1.02M |
| Total debt | - | - | - | - | - | - | $1.1K | $28.1K | $693.7K | $1.02M |
| Total liabilities | $6.42M | $5.37M | $4.15M | $2.96M | $2.67M | $2.07M | $1.64M | $1.33M | $1.50M | $3.40M |
| Shareholders' equity | $20.93M | $14.59M | $11.79M | $10.58M | $263.0K | $1.97M | $5.44M | $6.58M | $4.86M | -$821.5K |
Cash flow
| Line item | Dec 31, 2025 | Dec 31, 2024 | Jun 30, 2022 | Jun 30, 2021 | Jun 30, 2020 | Jun 30, 2019 | Jun 30, 2018 | Jun 30, 2017 | Jun 30, 2016 | Jun 30, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$27.63M | -$14.73M | -$20.39M | -$18.86M | -$7.93M | -$6.33M | -$9.85M | -$8.02M | -$5.15M | -$3.85M |
| Capital expenditures | $76.1K | $57.9K | $180.0K | - | - | - | - | - | - | - |
| Free cash flow | -$27.71M | -$14.79M | -$20.57M | - | - | - | - | - | - | - |
| Investing cash flow | -$1.34M | -$6.05M | - | $964.0K | - | - | -$12.6K | -$21.0K | -$16.8K | - |
| Financing cash flow | $19.93M | $29.77M | $21.64M | $26.04M | $6.60M | $4.07M | $9.25M | $8.47M | $9.57M | $847.8K |
| Stock-based compensation | $6.42M | $1.96M | - | - | - | $426.0K | $495.9K | $124.7K | $394.1K | $186.9K |
| Depreciation and amortization | $71.3K | $116.7K | - | - | - | - | - | - | - | - |
Key ratios
| Line item | Dec 31, 2025 | Dec 31, 2024 | Jun 30, 2022 | Jun 30, 2021 | Jun 30, 2020 | Jun 30, 2019 | Jun 30, 2018 | Jun 30, 2017 | Jun 30, 2016 | Jun 30, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net income growth, YoY | - | - | - | - | - | - | 37.8% | -8.8% | - | - |
| Return on equity | -143.6% | -148.6% | -192.1% | -362.0% | -3470.0% | -409.0% | 204.9% | 122.9% | 182.5% | - |
| Return on assets | -109.9% | -108.6% | -142.1% | -282.8% | -310.6% | -199.3% | 157.4% | 102.2% | 139.5% | -168.8% |
| Current ratio | 0.78 | 3.68 | 3.32 | 4.24 | 1.07 | 1.94 | 4.30 | 6.03 | 10.07 | 3.02 |
| Debt to equity | - | - | - | - | - | - | 0.00 | 0.00 | 0.14 | - |
Income statement
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Mar 31, 2023 | Dec 31, 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | - | - |
| Research and development | $6.62M | $5.23M | $6.06M | $4.97M | $4.93M | $4.58M | $3.98M | $2.95M | $2.82M | $3.59M | $2.00M | $2.06M |
| Selling, general and admin | $2.14M | $2.30M | -$1.56M | $1.76M | $1.86M | $2.02M | $1.28M | $783.5K | $795.7K | $1.02M | $1.30M | $1.44M |
| Interest expense | $467.6K | $28.0K | $608.8K | $16.5K | - | - | $522.8K | $2.00M | $1.36M | $255.1K | - | - |
| Net income | -$9.22M | -$7.54M | -$6.76M | -$7.10M | -$9.52M | -$6.66M | -$6.00M | -$5.58M | -$5.27M | -$4.84M | -$3.26M | -$3.45M |
| EPS, basic | -$0.14 | -$0.13 | -$0.13 | -$0.14 | -$0.21 | -$0.15 | - | -$0.54 | -$0.43 | -$0.40 | -$1.94 | -$2.10 |
| EPS, diluted | -$0.14 | -$0.13 | -$0.13 | -$0.14 | -$0.21 | -$0.15 | - | -$0.54 | -$0.43 | -$0.40 | - | - |
| Diluted shares | 64.0M | 60.0M | - | 50.7M | 44.6M | 43.4M | - | 12.2M | 12.2M | 12.2M | - | - |
Balance sheet
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Mar 31, 2023 | Dec 31, 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $996.0K | $6.30M | $3.62M | $2.70M | $8.51M | $6.22M | $12.66M | $19.60M | $12.31M | $4.46M | $3.04M | $14.25M |
| Current assets | $1.66M | $6.98M | $4.62M | $3.50M | $12.54M | $14.33M | $19.61M | $3.48M | $5.53M | $6.75M | $6.02M | $9.18M |
| Goodwill | $10.74M | $10.74M | $10.74M | $13.55M | $13.55M | - | - | - | - | - | - | - |
| Total assets | $31.75M | $29.70M | $27.35M | $25.70M | $34.62M | $14.64M | $19.97M | $4.14M | $6.20M | $7.45M | $6.74M | $9.92M |
| Current liabilities | $9.26M | $6.07M | $5.92M | $8.83M | $15.17M | $4.78M | $5.33M | $2.26M | $2.26M | $1.34M | $2.79M | $3.24M |
| Total debt | $3.60M | - | - | - | - | - | - | - | - | - | - | - |
| Total liabilities | $13.25M | $6.51M | $6.42M | $8.92M | $15.17M | $4.78M | $5.37M | $2.44M | $2.44M | $1.52M | $2.95M | $3.32M |
| Shareholders' equity | $18.50M | $23.19M | $20.93M | $16.78M | $19.45M | $9.86M | $14.59M | -$2.77M | -$6.96M | -$6.07M | $3.79M | $12.30M |
Cash flow
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Mar 31, 2023 | Dec 31, 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$8.63M | -$4.41M | -$5.56M | -$11.09M | -$6.25M | -$4.74M | -$2.60M | -$1.89M | -$5.07M | -$3.83M | -$1.83M | -$2.16M |
| Capital expenditures | $137.0K | $48.8K | $27.9K | $0 | $5.6K | $42.7K | $21.4K | $0 | - | - | $0 | $0 |
| Free cash flow | -$8.77M | -$4.46M | -$5.58M | -$11.09M | -$6.25M | -$4.78M | -$2.62M | -$1.89M | - | - | -$1.83M | -$2.16M |
| Investing cash flow | -$137.0K | -$48.8K | -$27.9K | $0 | -$156.5K | -$1.15M | -$823.5K | -$5.19M | - | - | $0 | $0 |
| Financing cash flow | $3.47M | $7.14M | $6.51M | $5.27M | $8.70M | -$547.9K | -$3.52M | $15.71M | $12.95M | $4.63M | -$2.0K | -$50.0K |
| Stock-based compensation | $2.14M | $2.80M | $2.15M | $1.45M | $1.41M | $1.42M | $1.08M | $269.3K | $275.5K | $334.6K | - | - |
| Depreciation and amortization | $28.1K | $23.5K | $22.5K | $21.3K | $13.4K | $14.1K | $17.6K | $29.1K | $35.6K | $34.3K | - | - |
Key ratios
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Mar 31, 2023 | Dec 31, 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current ratio | 0.18 | 1.15 | 0.78 | 0.40 | 0.83 | 3.00 | 3.68 | 1.54 | 2.45 | 5.04 | 2.16 | 2.83 |
| Debt to equity | 0.19 | - | - | - | - | - | - | - | - | - | - | - |
Source: XBRL data TuHURA Biosciences Inc. files with the SEC, latest filing dated Aug 14, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.
Per-share figures are as filed. The filings show no stock split in these periods.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
HURA peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| HURA | $0 | - | -$30.92M | - | $105.8M |
| LLY | $86.46B | +45.5% | $27.58B | 31.9% | $1.33T |
| JNJ | $99.33B | +7.8% | $16.09B | 16.2% | $679.13B |
| ABBV | $66.01B | +10.7% | $10.34B | 15.7% | $518.44B |
| MRK | $67.38B | +4.9% | $2.45B | 3.6% | $366.73B |
| NVS | $54.53B | +8.4% | $13.98B | 25.6% | $312.35B |
| AZN | $58.74B | +8.6% | $10.22B | 17.4% | $293.69B |
| ABT | $48.23B | +10.0% | $4.70B | 9.7% | $191.40B |
| NVO | DKK 309.06B | +6.4% | DKK 102.43B | 33.1% | $183.23B |
HURA FAQ
7 questionsWhat is HURA revenue?
TuHURA Biosciences Inc. (HURA) reported $0 of revenue for the twelve months ended Mar 31, 2026. Revenue for fiscal 2025 was $0.Is HURA profitable?
No. TuHURA Biosciences Inc. reported a net loss of $30.92M for the twelve months ended Mar 31, 2026.How much cash and debt does HURA have?
TuHURA Biosciences Inc. reported $996.0K in cash and cash equivalents and $3.60M of debt on its most recent balance sheet in SEC filings.What is HURA free cash flow?
TuHURA Biosciences Inc. generated -$27.39M of free cash flow for the twelve months ended Mar 31, 2026, which is operating cash flow of -$27.30M less capital expenditures.What is HURA earnings per share?
Diluted earnings per share were -$0.61 for the twelve months ended Mar 31, 2026, from SEC filings, restated for any stock split those filings show.When did HURA last report financial results?
The latest statements here come from TuHURA Biosciences Inc.'s 10-Q filed on Aug 14, 2026, covering the period ended Jun 30, 2026.Where does this HURA financial data come from?
Quantisnow builds these statements from the structured XBRL data TuHURA Biosciences Inc. files with the SEC. It is provided for information only and is not investment advice.